ELL is an inclusion criterion in 87 clinical trials for acute myeloid leukemia, of which 39 are open and 48 are closed. Of the trials that contain ELL status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 28 are phase 1 (10 open), 14 are phase 1/phase 2 (8 open), 32 are phase 2 (15 open), 1 is phase 2/phase 3 (1 open), 8 are phase 3 (5 open), and 3 are no phase specified (0 open) [4].

ELL is an inclusion criterion in 49 clinical trials for myelodysplastic syndromes, of which 27 are open and 22 are closed. Of the trials that contain ELL status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (0 open), 21 are phase 1 (10 open), 6 are phase 1/phase 2 (5 open), 18 are phase 2 (10 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 36 clinical trials for acute lymphoblastic leukemia, of which 19 are open and 17 are closed. Of the trials that contain ELL status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 15 are phase 1 (7 open), 2 are phase 1/phase 2 (2 open), 15 are phase 2 (8 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 28 clinical trials for chronic myeloid leukemia, of which 17 are open and 11 are closed. Of the trials that contain ELL status and chronic myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 11 are phase 1 (7 open), 4 are phase 1/phase 2 (4 open), 11 are phase 2 (6 open), and 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 24 clinical trials for primary myelofibrosis, of which 23 are open and 1 is closed. Of the trials that contain ELL status and primary myelofibrosis as inclusion criteria, 5 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), and 8 are phase 3 (8 open) [4].

ELL is an inclusion criterion in 21 clinical trials for hodgkin lymphoma, of which 12 are open and 9 are closed. Of the trials that contain ELL status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (6 open), and 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 20 clinical trials for myelofibrosis, of which 15 are open and 5 are closed. Of the trials that contain ELL status and myelofibrosis as inclusion criteria, 2 are early phase 1 (0 open), 8 are phase 1 (6 open), 3 are phase 1/phase 2 (3 open), 4 are phase 2 (3 open), and 3 are phase 3 (3 open) [4].

ELL is an inclusion criterion in 17 clinical trials for myelofibrosis transformation in essential thrombocythemia, of which 16 are open and 1 is closed. Of the trials that contain ELL status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (3 open), and 8 are phase 3 (8 open) [4].

ELL is an inclusion criterion in 17 clinical trials for non-hodgkin lymphoma, of which 10 are open and 7 are closed. Of the trials that contain ELL status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 8 are phase 2 (6 open) [4].

ELL is an inclusion criterion in 16 clinical trials for polycythemia vera, post-polycythemic myelofibrosis phase, of which 15 are open and 1 is closed. Of the trials that contain ELL status and polycythemia vera, post-polycythemic myelofibrosis phase as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 8 are phase 3 (8 open) [4].

ELL is an inclusion criterion in 14 clinical trials for chronic lymphocytic leukemia, of which 9 are open and 5 are closed. Of the trials that contain ELL status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (5 open), and 1 is phase 3 (0 open) [4].

ELL is an inclusion criterion in 14 clinical trials for multiple myeloma, of which 9 are open and 5 are closed. Of the trials that contain ELL status and multiple myeloma as inclusion criteria, 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 12 clinical trials for acute biphenotypic leukemia, of which 5 are open and 7 are closed. Of the trials that contain ELL status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 12 clinical trials for chronic myelomonocytic leukemia, of which 9 are open and 3 are closed. Of the trials that contain ELL status and chronic myelomonocytic leukemia as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (2 open) [4].

ELL is an inclusion criterion in 9 clinical trials for Burkitt lymphoma, of which 4 are open and 5 are closed. Of the trials that contain ELL status and Burkitt lymphoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 8 clinical trials for myeloproliferative neoplasm, of which 3 are open and 5 are closed. Of the trials that contain ELL status and myeloproliferative neoplasm as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 8 clinical trials for secondary myelofibrosis, of which 8 are open and 0 are closed. Of the trials that contain ELL status and secondary myelofibrosis as inclusion criteria, 2 are phase 1 (2 open), 5 are phase 2 (5 open), and 1 is phase 2/phase 3 (1 open) [4].

ELL is an inclusion criterion in 7 clinical trials for acute leukemia, of which 2 are open and 5 are closed. Of the trials that contain ELL status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 7 clinical trials for anaplastic large cell lymphoma, of which 3 are open and 4 are closed. Of the trials that contain ELL status and anaplastic large cell lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain ELL status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [4].

ELL is an inclusion criterion in 7 clinical trials for mantle cell lymphoma, of which 2 are open and 5 are closed. Of the trials that contain ELL status and mantle cell lymphoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 6 clinical trials for follicular lymphoma, of which 2 are open and 4 are closed. Of the trials that contain ELL status and follicular lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 6 clinical trials for marginal zone lymphoma, of which 2 are open and 4 are closed. Of the trials that contain ELL status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 6 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 5 are open and 1 is closed. Of the trials that contain ELL status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [4].

ELL is an inclusion criterion in 5 clinical trials for lymphoma, of which 3 are open and 2 are closed. Of the trials that contain ELL status and lymphoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

ELL is an inclusion criterion in 5 clinical trials for small lymphocytic lymphoma, of which 2 are open and 3 are closed. Of the trials that contain ELL status and small lymphocytic lymphoma as inclusion criteria, 4 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

ELL is an inclusion criterion in 4 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 3 are closed. Of the trials that contain ELL status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 1 is closed. Of the trials that contain ELL status and diffuse large B-cell lymphoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain ELL status and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 4 clinical trials for prolymphocytic leukemia, of which 2 are open and 2 are closed. Of the trials that contain ELL status and prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 4 clinical trials for refractory anemia with excess blasts, of which 2 are open and 2 are closed. Of the trials that contain ELL status and refractory anemia with excess blasts as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (1 open) [4].

ELL is an inclusion criterion in 3 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ELL status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 3 clinical trials for lymphoblastic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ELL status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

ELL is an inclusion criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 0 are open and 3 are closed. Of the trials that contain ELL status and lymphoplasmacytic lymphoma as inclusion criteria, 2 are phase 2 (0 open) and 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ELL status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [4].

ELL is an inclusion criterion in 2 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 2 are open and 0 are closed. Of the trials that contain ELL status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 2 are phase 2 (2 open) [4].

ELL is an inclusion criterion in 2 clinical trials for acute undifferentiated leukemia, of which 2 are open and 0 are closed. Of the trials that contain ELL status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain ELL status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain ELL status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [4].

ELL is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain ELL status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain ELL status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

ELL is an inclusion criterion in 2 clinical trials for mediastinal large B-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain ELL status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 1 is open and 1 is closed. Of the trials that contain ELL status and mixed phenotype acute leukemia as inclusion criteria, 2 are phase 2 (1 open) [4].

ELL is an inclusion criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 1 is closed. Of the trials that contain ELL status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [4].

ELL is an inclusion criterion in 2 clinical trials for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 1 is closed. Of the trials that contain ELL status and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 2 are phase 2 (1 open) [4].

ELL is an inclusion criterion in 2 clinical trials for plasma cell leukemia, of which 0 are open and 2 are closed. Of the trials that contain ELL status and plasma cell leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [4].

ELL is an inclusion criterion in 2 clinical trials for secondary acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain ELL status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 2 clinical trials for T-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain ELL status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 2 clinical trials for therapy-related myelodysplastic syndrome, of which 2 are open and 0 are closed. Of the trials that contain ELL status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for acute erythroid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ELL status and acute erythroid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains ELL status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [4].

ELL is an inclusion criterion in 1 clinical trial for acute megakaryoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ELL status and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for acute promyelocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains ELL status and acute promyelocytic leukemia as inclusion criteria, 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 1 clinical trial for adult acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ELL status and adult acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains ELL status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

ELL is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains ELL status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for atypical Burkitt/Burkitt-like lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ELL status and atypical Burkitt/Burkitt-like lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains ELL status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ELL status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for B-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains ELL status and B-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

ELL is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains ELL status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

ELL is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma activated B-cell type, of which 1 is open and 0 are closed. Of the trial that contains ELL status and diffuse large B-cell lymphoma activated B-cell type as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma associated with chronic inflammation, of which 1 is open and 0 are closed. Of the trial that contains ELL status and diffuse large B-cell lymphoma associated with chronic inflammation as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains ELL status and diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for EBV-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains ELL status and EBV-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for EBV-positive mucocutaneous ulcer, of which 1 is open and 0 are closed. Of the trial that contains ELL status and EBV-positive mucocutaneous ulcer as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for essential thrombocythemia, of which 1 is open and 0 are closed. Of the trial that contains ELL status and essential thrombocythemia as inclusion criteria, 1 is phase 1 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ELL status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ELL is an inclusion criterion in 1 clinical trial for germinal center B-cell-like diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ELL status and germinal center B-cell-like diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains ELL status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains ELL status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for high grade B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains ELL status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ELL status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ELL status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for intravascular large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ELL status and intravascular large B-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for lymphomatoid granulomatosis, of which 1 is open and 0 are closed. Of the trial that contains ELL status and lymphomatoid granulomatosis as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains ELL status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains ELL status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

ELL is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains ELL status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ELL is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains ELL status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 1 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ELL status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains ELL status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ELL is an inclusion criterion in 1 clinical trial for overt primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains ELL status and overt primary myelofibrosis as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains ELL status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ELL is an inclusion criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ELL status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].

ELL is an inclusion criterion in 1 clinical trial for plasmablastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ELL status and plasmablastic lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains ELL status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for primary central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ELL status and primary central nervous system lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for primary cutaneous diffuse large B-cell lymphoma, leg type, of which 1 is open and 0 are closed. Of the trial that contains ELL status and primary cutaneous diffuse large B-cell lymphoma, leg type as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for primary effusion lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ELL status and primary effusion lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for refractory anemia, of which 0 are open and 1 is closed. Of the trial that contains ELL status and refractory anemia as inclusion criteria, 1 is phase 2 (0 open) [4].

ELL is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains ELL status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ELL is an inclusion criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains ELL status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains ELL status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

ELL is an inclusion criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ELL status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains ELL status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

ELL is an inclusion criterion in 1 clinical trial for T-cell/histiocyte-rich large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ELL status and T-cell/histiocyte-rich large B-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ELL status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ELL status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ELL status and triple-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ELL is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 1 is open and 0 are closed. Of the trial that contains ELL status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 2 (1 open) [4].